Antiviral treatment of a serious herpes simplex infection: XXXX .

@entity1 @entity1033 @entity410 @entity12948 @entity198 @entity5 @entity1269 @entity772 @entity272 @entity1662 @entity10 @entity221
Herpes simplex @entity198 is the most common cause of @entity5 in the western world. @entity1 usually have altered levels of consciousness, altered levels of mentation, @entity221 , @entity10 , and personality changes. These may progress to @entity1269 and @entity410 . Exact diagnosis must be established by brain biopsy and identification of the virus in biopsy material. There is a great need for a noninvasive test that is positive early in the disease. Without antiviral treatment the mortality rate is greater than 70%, and many survivors have serious disabilities. Both @entity12948 and @entity1033 decrease death and morbidity, but @entity1033 is the preferred drug. With @entity1033 about 40% of @entity1 will survive with normal development or minor levels of impairment but more than half of the @entity1 will die or suffer significant impairment. It is essential to treat early; @entity1 who are young and have not reached @entity772 or @entity1662 may show 65% recovery and return to normal function. Development of new antiviral drugs or other types of therapies is desirable. Herpetic @entity272 are likely to be more confusing than diagnostic because other types of @entity198 with @entity221 often precipitate recurrent herpes that is unrelated to the @entity198 .
